Renasant Bio
Berkeley, US · Founded 2022 · Delaware corporation · 35 employees on LinkedIn · 4 known investors
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.
Founders & leadership
Renasant Bio was founded in 2022 by Jeremy Reiter and Markus Delling.
JR
Jeremy ReiterScientific Co-Founder
MD
Markus DellingScientific Co-Founder
TG
Thomas GustafsonExecutive
EC
Emily ConleyExecutive
Board
EC
CM
Charlotte McKeeBoard director
DP
Deborah PalestrantinMember Board of DirectorsPartner, Executive Chair, 4:59 Initiative at 5AM Ventures
AF
Anna FrenchinBoard director
KB
NH
Natalie HollesinBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$55.5M disclosed across 2 rounds · 2024–2025
▶$25.5MraisedJul 2025 · 3 investors · BiotechnologyRule 506(b)
▶$25.5MraisedJul 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Emily ConleyExecutive Officer, Director
- Deborah PalestrantDirector
- Evan CaplanDirector
- Thomas GustafsonExecutive Officer
- Kevin BittermanDirector
- June LeeDirector
- Offering amount
- $25.5M
- Amount sold
- $25.5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$30MraisedJul 2025 · 4 investors · BiotechnologyRule 506(b)
▶$30MraisedJul 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Evan CaplanDirector
- Natalie HollesDirector
- Charlotte McKeeDirector
- Deborah PalestrantDirector
- Thomas GustafsonExecutive Officer
- Anna FrenchDirector
- Kevin BittermanDirector
- Emily ConleyExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Renasant Bio went on to found or lead other companies.
Competitors · 6
by search overlap
Octant Bio8 shared keywordsOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Radiant Biotherapeutics6 shared keywordsRadiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
Gannet BioChem5 shared keywordsGannet BioChem is a contract development and manufacturing organization (CDMO) specializing in polymer science, offering activated polymers, PEG chemistry, and bioconjugation services for complex therapeutics. It supports drug developers from early discovery through cGMP and commercial manufacturing.
Guardant Health5 shared keywordsGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Infinant Health4 shared keywordsInfinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.
Signant Health4 shared keywordsSignant Health provides eClinical technology and services for clinical trial data collection, including electronic data capture, patient and site data solutions, and scientific and operational support. It serves pharmaceutical sponsors and CROs running global clinical trials to generate high-quality data for trial decisions and regulatory submissions.
Companies competing with Renasant Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Renasant Bio do?
- Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.
- Who founded Renasant Bio?
- Renasant Bio was founded by Jeremy Reiter, Markus Delling in 2022.
- Who are Renasant Bio's investors?
- Renasant Bio's investors include 5AM Ventures, OrbiMed, Atlas Venture, Qiming Venture Partners USA.
- How much funding has Renasant Bio raised?
- Renasant Bio has disclosed $55.5M raised across 2 rounds.
- Where is Renasant Bio headquartered?
- Renasant Bio is headquartered in Berkeley, US.